Figure 4.

A new algorithm for choosing therapy for a patient with T2DM. *Cardiovascular outcome data for these drug classes are available for patients with A1C of 7% or higher, but achieving an A1C 6.5% or less should be the goal for most patients, as suggested by the ADA. **If GFR > 30 mL/min/1.7 m² and there is no other contraindication to metformin use. For GFR of 30–45 mL/min/1.7m² assess the benefits versus risks before starting. ***For GFR < 45 mL/min/1.7m² or less, patients should not be offered SGLT-2 inhibitors